EA200702093A1 - Антитела-миметики glp-1 человека, композиции, способы и их применение - Google Patents

Антитела-миметики glp-1 человека, композиции, способы и их применение

Info

Publication number
EA200702093A1
EA200702093A1 EA200702093A EA200702093A EA200702093A1 EA 200702093 A1 EA200702093 A1 EA 200702093A1 EA 200702093 A EA200702093 A EA 200702093A EA 200702093 A EA200702093 A EA 200702093A EA 200702093 A1 EA200702093 A1 EA 200702093A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glp
methods
mimetic
antibody
compositions
Prior art date
Application number
EA200702093A
Other languages
English (en)
Inventor
Кэрин Т. О`Нил
Кристен Пича
Original Assignee
Сентокор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентокор, Инк. filed Critical Сентокор, Инк.
Priority claimed from PCT/US2005/046884 external-priority patent/WO2007081302A2/en
Publication of EA200702093A1 publication Critical patent/EA200702093A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится по меньшей мере к одному новому антителу-миметику GLP-1 человека или к его конкретной части или варианту, включая выделенные нуклеиновые кислоты, кодирующие по меньшей мере одно антитело-миметик GLP-1 или его конкретную часть или вариант; к антителу-миметику GLP-1 или к его конкретным частям или вариантам; к векторам; к клеткам-хозяевам; к трансгенным животным или растениям, содержащим указанное антитело-миметик GLP-1; и к способам их получения и применения, включая приготовление терапевтических композиций, способы их введения и содержащие их устройства.
EA200702093A 2004-03-31 2005-12-22 Антитела-миметики glp-1 человека, композиции, способы и их применение EA200702093A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55798304P 2004-03-31 2004-03-31
US61298104P 2004-09-24 2004-09-24
PCT/US2005/010456 WO2005097175A2 (en) 2004-03-31 2005-03-28 Human glp-1 mimetibodies, compositions, methods and uses
PCT/US2005/046884 WO2007081302A2 (en) 2005-03-28 2005-12-22 Human glp-1 mimetibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
EA200702093A1 true EA200702093A1 (ru) 2009-06-30

Family

ID=35125618

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200601603A EA011583B1 (ru) 2004-03-31 2005-03-28 Миметические антитела glp-1 человека, композиции, способы и применения
EA200702093A EA200702093A1 (ru) 2004-03-31 2005-12-22 Антитела-миметики glp-1 человека, композиции, способы и их применение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200601603A EA011583B1 (ru) 2004-03-31 2005-03-28 Миметические антитела glp-1 человека, композиции, способы и применения

Country Status (17)

Country Link
US (1) US20070135338A1 (ru)
EP (1) EP1750754A4 (ru)
JP (1) JP2008537873A (ru)
KR (1) KR20070004078A (ru)
AR (1) AR049014A1 (ru)
AU (1) AU2005231359A1 (ru)
BR (1) BRPI0509528A (ru)
CA (1) CA2563379A1 (ru)
CR (1) CR8706A (ru)
EA (2) EA011583B1 (ru)
IL (1) IL178432A0 (ru)
MX (1) MXPA06011425A (ru)
NO (1) NO20064953L (ru)
SG (1) SG151315A1 (ru)
TW (1) TW200602491A (ru)
WO (1) WO2005097175A2 (ru)
ZA (1) ZA200709266B (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081302A2 (en) * 2005-03-28 2007-07-19 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
EP1906991A2 (en) * 2004-06-28 2008-04-09 Novo Nordisk A/S Use of glp-1 receptor agonists and/or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i, diabetes type ii and impaired pancreatic beta-cell function
WO2006047535A2 (en) * 2004-10-25 2006-05-04 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
BRPI0519241A2 (pt) * 2004-12-22 2009-01-06 Centocor Inc agonistas, composiÇÕes, mÉtodos e usos de glp-1
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
EP1868650B1 (en) 2005-04-15 2018-10-03 MacroGenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2658673A1 (en) 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
PL1767545T3 (pl) 2005-09-22 2010-04-30 Biocompatibles Uk Ltd Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
BRPI0617515A2 (pt) * 2005-10-24 2011-07-26 Centocor Inc mimeticorpos, polipeptÍdeos, composiÇÕes, mÉtodos e usos de glp-2
EP1968645A4 (en) * 2005-12-22 2009-11-04 Centocor Ortho Biotech Inc HUMAN GLP-1 MIMETIC BODIES AND COMPOSITIONS FOR THE TREATMENT OF ADIPOSITAS AND RELATED DISEASES, METHODS AND APPLICATIONS
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
TW200821386A (en) 2006-07-18 2008-05-16 Centocor Inc Human GLP-1 mimetibodies, compositions, methods and uses
WO2008028117A2 (en) * 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
TW200843794A (en) 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
US20090181037A1 (en) * 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
ES2589912T3 (es) 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
WO2010033279A2 (en) * 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US20110129522A1 (en) * 2008-07-21 2011-06-02 Transpharma Medical Ltd. Transdermal system for extended delivery of incretins and incretn mimetic peptides
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
AU2009335798B2 (en) * 2008-12-19 2014-11-27 Macrogenics, Inc. Covalent diabodies and uses thereof
US20100291160A1 (en) * 2009-05-13 2010-11-18 Carver David R Pharmaceutical system for trans-membrane delivery
SI2486141T1 (en) 2009-10-07 2018-06-29 Macrogenics, Inc. FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE
WO2011044589A2 (en) * 2009-10-09 2011-04-14 Board Of Regents, The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
EP2494061B1 (en) 2009-10-29 2017-01-25 Janssen Biotech, Inc. Antibody glycosylation variants
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
NZ701539A (en) 2010-03-04 2015-04-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
ES2626013T3 (es) 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
LT2968520T (lt) 2013-03-14 2021-09-27 Macrogenics, Inc. Bispecifinės molekulės, kurios yra imunoreaktyvios imuninių efektorių ląstelėms, kurios ekspresuoja aktyvuojantį receptorių
JP6457484B2 (ja) 2013-04-03 2019-01-23 サノフイＳａｎｏｆｉ インスリンの長時間作用型製剤による糖尿病の治療
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PE20190353A1 (es) 2016-04-15 2019-03-07 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2021195344A2 (en) * 2020-03-25 2021-09-30 The General Hospital Corporation Compositions and methods for diabetes treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) * 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US4767402A (en) * 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
ATE189124T1 (de) 1991-07-02 2000-02-15 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1994006498A1 (en) 1992-09-23 1994-03-31 Fisons Plc Inhalation device
DK0665759T3 (da) 1992-10-19 1999-08-23 Dura Pharma Inc Tørpulverinhalator
US5643252A (en) * 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US5849695A (en) * 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
WO1994016970A1 (en) 1993-01-19 1994-08-04 Glaxo Group Limited Device
CZ206195A3 (en) * 1993-02-12 1996-04-17 Univ Leland Stanford Junior Controlled transcription of target genes and other biological materials
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1996036883A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Immunoassay for glucagon like protein 1 (glp-1) in plasma
US5730723A (en) * 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
WO1997025086A2 (en) 1996-01-03 1997-07-17 Glaxo Group Limited Inhalation device
UA65549C2 (ru) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Применение аналогов и производных glp-1 для периферического введения для борьбы с ожирением
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6849719B2 (en) * 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
AU6522199A (en) * 1998-10-21 2000-05-08 Zymogenetics Inc. Secreted protein zsig49
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU2003218432A1 (en) * 2002-03-26 2003-10-13 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
MXPA05000202A (es) * 2002-06-28 2005-09-30 Johnson & Johnson Cuerpos mimeicos ch1-deletados de epo de mimetica de mamifero.
WO2004002417A2 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
WO2005097175A3 (en) 2009-11-19
BRPI0509528A (pt) 2007-08-07
NO20064953L (no) 2006-12-18
MXPA06011425A (es) 2007-03-12
US20070135338A1 (en) 2007-06-14
SG151315A1 (en) 2009-04-30
AU2005231359A1 (en) 2005-10-20
KR20070004078A (ko) 2007-01-05
CR8706A (es) 2009-01-16
WO2005097175A2 (en) 2005-10-20
IL178432A0 (en) 2007-02-11
AR049014A1 (es) 2006-06-21
TW200602491A (en) 2006-01-16
JP2008537873A (ja) 2008-10-02
EA011583B1 (ru) 2009-04-28
EP1750754A4 (en) 2010-09-22
EA200601603A1 (ru) 2007-08-31
CA2563379A1 (en) 2005-10-20
ZA200709266B (en) 2009-05-27
EP1750754A2 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
EA200702093A1 (ru) Антитела-миметики glp-1 человека, композиции, способы и их применение
EA200701362A1 (ru) Агонисты glp-1, композиции, способы и применения
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
EA200600525A1 (ru) Еро-имитирующие миметичекие антитела человека с центральной шарнирной областью, композиции, способы и применения
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
UA108066C2 (uk) Білки, що зв'язуються з cgrp-рецепторами людини
ATE509953T1 (de) Antikörper gegen den erythropoietinrezeptor und verwendungen davon
UY29128A1 (es) Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos
BRPI0921665A2 (pt) humanizado anti-il-6 anticorpos
BRPI0214168B8 (pt) anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
EA201070479A1 (ru) Человеческие антиамилоидные антитела, композиции, способы и их применение
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
MXPA02008239A (es) Gen humano de la esquizofrenia.
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
EA200501711A1 (ru) Семейство секретируемых белков
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
NO20075272L (no) Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser
SE0100873D0 (sv) Method of treatment
WO2008048871A3 (en) Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses
AU9683401A (en) Flea peritrophin nucleic acid molecules, proteins and uses thereof